Cargando…
Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients
To determine whether in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue lymphoma (MALT), delayed–time-point 2-(18)F-fluoro-2-deoxy-d-glucose-positron emission tomography ((18)F-FDG-PET) performs better than standard–time-point (18)F-FDG-PET. MATERIALS...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703065/ https://www.ncbi.nlm.nih.gov/pubmed/26402137 http://dx.doi.org/10.1097/RLU.0000000000001005 |
_version_ | 1782408690665521152 |
---|---|
author | Mayerhoefer, Marius E. Giraudo, Chiara Senn, Daniela Hartenbach, Markus Weber, Michael Rausch, Ivo Kiesewetter, Barbara Herold, Christian J. Hacker, Marcus Pones, Matthias Simonitsch-Klupp, Ingrid Müllauer, Leonhard Dolak, Werner Lukas, Julius Raderer, Markus |
author_facet | Mayerhoefer, Marius E. Giraudo, Chiara Senn, Daniela Hartenbach, Markus Weber, Michael Rausch, Ivo Kiesewetter, Barbara Herold, Christian J. Hacker, Marcus Pones, Matthias Simonitsch-Klupp, Ingrid Müllauer, Leonhard Dolak, Werner Lukas, Julius Raderer, Markus |
author_sort | Mayerhoefer, Marius E. |
collection | PubMed |
description | To determine whether in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue lymphoma (MALT), delayed–time-point 2-(18)F-fluoro-2-deoxy-d-glucose-positron emission tomography ((18)F-FDG-PET) performs better than standard–time-point (18)F-FDG-PET. MATERIALS AND METHODS: Patients with untreated histologically verified MALT lymphoma, who were undergoing pretherapeutic (18)F-FDG-PET/computed tomography (CT) and consecutive (18)F-FDG-PET/magnetic resonance imaging (MRI), using a single (18)F-FDG injection, in the course of a larger-scale prospective trial, were included. Region-based sensitivity and specificity, and patient-based sensitivity of the respective (18)F-FDG-PET scans at time points 1 (45–60 minutes after tracer injection, TP1) and 2 (100–150 minutes after tracer injection, TP2), relative to the reference standard, were calculated. Lesion-to-liver and lesion-to-blood SUV(max) (maximum standardized uptake values) ratios were also assessed. RESULTS: (18)F-FDG-PET at TP1 was true positive in 15 o f 23 involved regions, and (18)F-FDG-PET at TP2 was true-positive in 20 of 23 involved regions; no false-positive regions were noted. Accordingly, region-based sensitivities and specificities were 65.2% (confidence interval [CI], 45.73%–84.67%) and 100% (CI, 100%-100%) for (18)F-FDG-PET at TP1; and 87.0% (CI, 73.26%–100%) and 100% (CI, 100%-100%) for (18)F-FDG-PET at TP2, respectively. FDG-PET at TP1 detected lymphoma in at least one nodal or extranodal region in 7 of 13 patients, and (18)F-FDG-PET at TP2 in 10 of 13 patients; accordingly, patient-based sensitivity was 53.8% (CI, 26.7%–80.9%) for (18)F-FDG-PET at TP1, and 76.9% (CI, 54.0%–99.8%) for (18)F-FDG-PET at TP2. Lesion-to-liver and lesion-to-blood maximum standardized uptake value ratios were significantly lower at TP1 (ratios, 1.05 ± 0.40 and 1.52 ± 0.62) than at TP2 (ratios, 1.67 ± 0.74 and 2.56 ± 1.10; P = 0.003 and P = 0.001). CONCLUSIONS: Delayed–time-point imaging may improve (18)F-FDG-PET in MALT lymphoma. |
format | Online Article Text |
id | pubmed-4703065 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-47030652016-01-19 Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients Mayerhoefer, Marius E. Giraudo, Chiara Senn, Daniela Hartenbach, Markus Weber, Michael Rausch, Ivo Kiesewetter, Barbara Herold, Christian J. Hacker, Marcus Pones, Matthias Simonitsch-Klupp, Ingrid Müllauer, Leonhard Dolak, Werner Lukas, Julius Raderer, Markus Clin Nucl Med Original Articles To determine whether in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue lymphoma (MALT), delayed–time-point 2-(18)F-fluoro-2-deoxy-d-glucose-positron emission tomography ((18)F-FDG-PET) performs better than standard–time-point (18)F-FDG-PET. MATERIALS AND METHODS: Patients with untreated histologically verified MALT lymphoma, who were undergoing pretherapeutic (18)F-FDG-PET/computed tomography (CT) and consecutive (18)F-FDG-PET/magnetic resonance imaging (MRI), using a single (18)F-FDG injection, in the course of a larger-scale prospective trial, were included. Region-based sensitivity and specificity, and patient-based sensitivity of the respective (18)F-FDG-PET scans at time points 1 (45–60 minutes after tracer injection, TP1) and 2 (100–150 minutes after tracer injection, TP2), relative to the reference standard, were calculated. Lesion-to-liver and lesion-to-blood SUV(max) (maximum standardized uptake values) ratios were also assessed. RESULTS: (18)F-FDG-PET at TP1 was true positive in 15 o f 23 involved regions, and (18)F-FDG-PET at TP2 was true-positive in 20 of 23 involved regions; no false-positive regions were noted. Accordingly, region-based sensitivities and specificities were 65.2% (confidence interval [CI], 45.73%–84.67%) and 100% (CI, 100%-100%) for (18)F-FDG-PET at TP1; and 87.0% (CI, 73.26%–100%) and 100% (CI, 100%-100%) for (18)F-FDG-PET at TP2, respectively. FDG-PET at TP1 detected lymphoma in at least one nodal or extranodal region in 7 of 13 patients, and (18)F-FDG-PET at TP2 in 10 of 13 patients; accordingly, patient-based sensitivity was 53.8% (CI, 26.7%–80.9%) for (18)F-FDG-PET at TP1, and 76.9% (CI, 54.0%–99.8%) for (18)F-FDG-PET at TP2. Lesion-to-liver and lesion-to-blood maximum standardized uptake value ratios were significantly lower at TP1 (ratios, 1.05 ± 0.40 and 1.52 ± 0.62) than at TP2 (ratios, 1.67 ± 0.74 and 2.56 ± 1.10; P = 0.003 and P = 0.001). CONCLUSIONS: Delayed–time-point imaging may improve (18)F-FDG-PET in MALT lymphoma. Lippincott Williams & Wilkins 2016-02 2016-01-18 /pmc/articles/PMC4703065/ /pubmed/26402137 http://dx.doi.org/10.1097/RLU.0000000000001005 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | Original Articles Mayerhoefer, Marius E. Giraudo, Chiara Senn, Daniela Hartenbach, Markus Weber, Michael Rausch, Ivo Kiesewetter, Barbara Herold, Christian J. Hacker, Marcus Pones, Matthias Simonitsch-Klupp, Ingrid Müllauer, Leonhard Dolak, Werner Lukas, Julius Raderer, Markus Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients |
title | Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients |
title_full | Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients |
title_fullStr | Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients |
title_full_unstemmed | Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients |
title_short | Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients |
title_sort | does delayed-time-point imaging improve 18f-fdg-pet in patients with malt lymphoma?: observations in a series of 13 patients |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703065/ https://www.ncbi.nlm.nih.gov/pubmed/26402137 http://dx.doi.org/10.1097/RLU.0000000000001005 |
work_keys_str_mv | AT mayerhoefermariuse doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients AT giraudochiara doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients AT senndaniela doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients AT hartenbachmarkus doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients AT webermichael doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients AT rauschivo doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients AT kiesewetterbarbara doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients AT heroldchristianj doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients AT hackermarcus doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients AT ponesmatthias doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients AT simonitschkluppingrid doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients AT mullauerleonhard doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients AT dolakwerner doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients AT lukasjulius doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients AT raderermarkus doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients |